Francesco Alessandrini

Dr. Francesco Alessandrini

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
FAFrancesco Alessandrini
Francesco Alessandrini
LMLaura Menotti
Laura Menotti
EAElisa Avitabile
Elisa Avitabile
IAIrene Appolloni
Irene Appolloni
DCDavide Ceresa
Davide Ceresa
PMPaolo Malatesta
Paolo Malatesta

18 August 2023 in Science Advances
Verified
Journal Article
Open access
JMJacob R. Mann
Jacob R. Mann
EMElizabeth D. McKenna
Elizabeth D. McKenna
DMDarilang Mawrie
Darilang Mawrie
VPVasileios Papakis
Vasileios Papakis
FAFrancesco Alessandrini
Francesco Alessandrini
EKEvangelos Kiskinis
Evangelos Kiskinis
Loss-of-function variants in NIMA-related kinase 1 (NEK1) constitute a major genetic cause of amyotrophic lateral sclerosis (ALS), accounting for 2 to 3% of all cases. However, how NEK1 mutations cause motor neuron (MN) dysfunction is unknown. Using mass spectrometry analyses for NEK1 interactors and NEK1-dependent expression changes, we find functional enrichment for proteins involved in the microtubule cytoskeleton and nucleocytoplasmic transport. We show that α-tubulin and importin-β1, two key proteins involved in these processes, are phosphorylated by NEK1 in vitro. NEK1 is essential for motor control and survival in Drosophila models in vivo, while using several induced pluripotent stem cell (iPSC)–MN models, including NEK1 knockdown, kinase inhibition, and a patient mutation, we find evidence for disruptions in microtubule homeostasis and nuclear import. Notably, stabilizing microtubules with two distinct classes of drugs restored NEK1-dependent deficits in both pathways. The capacity of NEK1 to modulate these processes that are critically involved in ALS pathophysiology renders this kinase a formidable therapeutic candidate.

1 November 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
FAFrancesco Alessandrini
Francesco Alessandrini
ICIlaria Cristofaro
Ilaria Cristofaro
MBMaria Di Bari
Maria Di Bari
JZJacopo Zasso
Jacopo Zasso
Luciano ContiLuciano Conti
Luciano Conti
Ada Maria TataAda Maria Tata
Ada Maria Tata

9 March 2020 in Cells
Verified
Journal Article
Open access
PDF file
ICIlaria Cristofaro
Ilaria Cristofaro
FAFrancesco Alessandrini
Francesco Alessandrini
ZSZaira Spinello
Zaira Spinello
CGClaudia Guerriero
Claudia Guerriero
MFMario Fiore
Mario Fiore
Ada Maria TataAda Maria Tata
Ada Maria Tata
Glioblastomas (GBM) are the most aggressive form of primary brain tumors in humans. A key feature of malignant gliomas is their cellular heterogeneity. In particular, the presence of an undifferentiated cell population of defined Glioblastoma Stem cells (GSCs) was reported. Increased expression of anti-apoptotic and chemo-resistance genes in GCSs subpopulation favors their high resistance to a broad spectrum of drugs. Our previous studies showed the ability of M2 muscarinic receptors to negatively modulate the cell growth in GBM cell lines and in the GSCs. The aim of this study was to better characterize the inhibitory effects of M2 receptors on cell proliferation and survival in GSCs and investigate the molecular mechanisms underlying the M2-mediated cell proliferation arrest and decreased survival. Moreover, we also evaluated the ability of M2 receptors to interfere with Notch1 and EGFR pathways, whose activation promotes GSCs proliferation. Our data demonstrate that M2 receptors activation impairs cell cycle progression and survival in the primary GSC lines analyzed (GB7 and GB8). Moreover, we also demonstrated the ability of M2 receptor to inhibit Notch1 and EGFR expression, highlighting a molecular interaction between M2 receptor and the Notch-1/EGFR pathways also in GSCs.

12 March 2018 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
CVChiara Villa
Chiara Villa
MCMarcello Campione
Marcello Campione
BSBeatriz Santiago‐González
Beatriz Santiago‐González
FAFrancesco Alessandrini
Francesco Alessandrini
SESilvia Erratico
Silvia Erratico
AMAngelo Monguzzi
Angelo Monguzzi

1 February 2019 in Cancer Letters
Verified
Journal Article
Closed access
IAIrene Appolloni
Irene Appolloni
FAFrancesco Alessandrini
Francesco Alessandrini
DCDavide Ceresa
Davide Ceresa
DMDaniela Marubbi
Daniela Marubbi
EGEleonora Gambini
Eleonora Gambini
PMPaolo Malatesta
Paolo Malatesta